A drug called bortezomib Injection 2.5mg is used to treat several cancers, including multiple myeloma and mantle cell lymphoma. As a proteasome inhibitor, bortezomib prevents the cell's proteasomes from performing their intended job. By preventing the activity of proteasomes, which are in charge of breaking down proteins, bortezomib prevents the growth and survival of cancer cells, ultimately causing their demise.
1. The cancer multiple myeloma, which damages plasma cells in the bone marrow, is treated with bortezomib as a component of combination therapy.
2. Mantle Cell Lymphoma: This non-Hodgkin's lymphoma variant, which develops from B-cells, is also treated with it.
The most common way to administer bortezomib is through an intravenous (IV) injection, which delivers the drug directly into the bloodstream through a vein. Depending on the type and stage of the cancer as well as the unique characteristics of the patient, the dosage and treatment plan may change.
Like other drugs, bortezomib has undesirable effects. Low blood cell counts, exhaustion, nausea, vomiting, diarrhoea, and peripheral neuropathy (tingling or numbness in the hands and feet) are a few of the most typical adverse effects. During or soon after the medicine delivery, some individuals may also have infusion-related effects.
While taking Bortezomib medication, patients must be continuously watched by their healthcare team in order to manage and treat any potential adverse effects.
The choice to use Bortezomib Injection 2.5mg, as with any cancer treatment, should be made by a licenced healthcare provider, taking into account the patient's unique medical history and condition. It's crucial to speak with a healthcare professional for thorough advice and direction if you have questions about Bortezomib Injection 2.5mg or you or someone you know has been prescribed it.